Experienced in Peripheral T-Cell Lymphoma

Dr. Daniel R. Couriel

Hematology Oncology | Oncology | Hematology
University Of Utah Adult Services
2596 F Rd, 
Grand Junction, CO 
Accepting New Patients
Experienced in Peripheral T-Cell Lymphoma
University Of Utah Adult Services
2596 F Rd, 
Grand Junction, CO 
OverviewInsuranceLocationsClinical Research

Overview

Daniel Couriel is a Hematologist Oncology specialist and an Oncologist in Grand Junction, Colorado. Dr. Couriel is rated as an Experienced provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. His top areas of expertise are Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Multiple Myeloma, Myelodysplastic Syndrome (MDS), and Bone Marrow Transplant. Dr. Couriel is currently accepting new patients.

His clinical research consists of co-authoring 84 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in MI
Hospital Affiliations
University Of Utah Hospital And Clinics
Languages Spoken
English
French
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Deseret Mutual Benefit Administrators
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Mountain Health
  • OTHER COMMERCIAL
  • POS
  • PPO
PacificSource
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Regence
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
Steward Health Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Utah Health
  • EPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

UNIVERSITY OF UTAH ADULT SERVICES
2596 F Rd, Grand Junction, CO 81505
Other Locations
UNIVERSITY OF UTAH ADULT SERVICES
1950 Circle Of Hope Dr, Salt Lake City, UT 84112

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Phase I Study Utilizing Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor Nivolumab for Relapsed/Refractory Lymphoma
Phase I Study Utilizing Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor Nivolumab for Relapsed/Refractory Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2025
Intervention Type: Drug, Biological
Study Drugs: TAA-T cells, Nivolumab
Study Phase: Phase 1
A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2025
Intervention Type: Drug, Procedure
Study Drugs: Lenalidomide, Bortezomib, Dexamethasone
Study Phase: Phase 3
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects With Hematologic Malignancies
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: February 08, 2023
Intervention Type: Biological
Study Drug: ProTmune Ex Vivo Programmed Mobilized Peripheral Cells
Study Phase: Phase 1/Phase 2
Pilot Study for the Treatment of Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease (GVHD) With GDC-0449 (GDC-0449)
Pilot Study for the Treatment of Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease (GVHD) With GDC-0449 (GDC-0449)
Enrollment Status: Terminated
Publish Date: July 19, 2021
Intervention Type: Other, Drug
Study Phase: Phase 2
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus Conventional Treatment for Treating Steroid Resistant Acute Graft-versus Host Disease
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus Conventional Treatment for Treating Steroid Resistant Acute Graft-versus Host Disease
Enrollment Status: Terminated
Publish Date: January 30, 2020
Intervention Type: Biological
Study Phase: Phase 3
View 4 Less Clinical Trials

84 Total Publications

Access barriers to hematopoietic stem cell transplantation and CAR T-cells in US.
Access barriers to hematopoietic stem cell transplantation and CAR T-cells in US.
Journal: Leukemia & lymphoma
Published: July 06, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Couriel's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 27 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile